IHC.L

Inspiration Healthcare Group Plc
Inspiration Health - Nominated adviser and broker
2nd August 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8546Y
Inspiration Healthcare Group PLC
02 August 2024
 

 

 

2 August 2024

Inspiration Healthcare Group plc

(the "Company")

 

Nominated Adviser and Broker

 

Inspiration Healthcare Group plc announces that following the completion of the all-share merger between Liberum Capital Limited and Panmure Gordon Group Limited, the Company's Nominated Adviser and Broker is Panmure Liberum Limited.

 

For further information, please contact:

 

Inspiration Healthcare Group plc

                                Tel: +44 (0)330 175 0000

Roy Davis, Executive Chair and Interim Chief Executive Officer

Alan Olby, Chief Financial Officer




Panmure Liberum Limited (Nominated Adviser & Broker)

                                Tel: +44 (0)20 3100 2000

Richard Lindley

Will King

Joshua Borlant


 


Walbrook PR Ltd (Media & IR)

Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com

Anna Dunphy

Mob: +44 (0) 7876 741 001

Stephanie Cuthbert

Mob: +44 (0) 7796 794 663

Louis Ashe-Jepson

Mob: +44 (0) 7747 515 393

 

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

 

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy.  In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and from its facility in Hailsham, East Sussex, and in the USA from its facility in Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBXGDIGBGDGSB]]>
TwitterFacebookLinkedIn